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Arsenic exposure through drinking water is a
global threat to human health. It is associated
with various human cancers such as skin,
lung, bladder, liver, and prostate and non-
cancerous outcomes such as pigmented skin
lesions, Blackfoot disease, diabetes, and
hypertension. Skin lesions such as hyperker-
atosis and hyperpigmentation are hallmarks
of chronic arsenic exposure and develop early
after exposure compared with cancerous out-
comes [National Research Council (NRC)
1999]. Previous studies have established the
relationship between drinking water arsenic
exposure and premalignant skin lesions
(Ahsan et al. 2000; NRC 1999). 
Mechanisms of human arsenic metabo-
lism and related disease susceptibility, includ-
ing hyperkeratosis and hyperpigmentation,
are not fully understood (Kitchin 2001).
Arsenic methylation has been considered a
detoxification mechanism; however, it has
been suggested that the methylated urinary
metabolites of arsenic, specifically mono-
methylarsonous acid (MMAIII) and dimethyl-
arsinous acid (DMAIII), are more toxic than
their precursor arsenite (AsIII) (Del Razo et al.
2001; Kitchin 2001; Styblo et al. 2000).
MMAIII and DMAIII may be responsible for
some of the effects of chronic arsenic expo-
sure (Del Razo et al. 2001). Urinary arsenic
species are 10–20% inorganic arsenic,
10–15% monomethylarsenic acid (MMA),
60–80% dimethylarsenic acid (DMA), and
the methylated metabolites exist in trivalent
and pentavalent forms (Kitchin 2001).
Urinary arsenic species have been used as bio-
markers of individual methylation ability and
short-term exposure status (Chen et al.
2003a, 2003b).
Differences in disease susceptibility may
be due to individual variability in biotransfor-
mation of arsenic, and polymorphisms in
metabolic genes may contribute to this vari-
ability (Loffredo et al. 2003; Vahter 2000).
Because arsenic methylation appears to affect
its toxicity, it is essential to identify factors
that impact methylation capacity and to bet-
ter understand risk of disease.
Glutathione S-transferase (GST) poly-
morphisms alone and in concert with envi-
ronmental exposures are associated with
disease outcomes. Polymorphisms in GST
genes may have effects on the behavior of sev-
eral enzymes involved with the maintenance
of cellular glutathione (GSH) levels (Strange
et al. 2000). GSTs are a superfamily of
enzymes that are key in the detoxification
step of phase II metabolism. One role of the
GSTs is to catalyze the conjugation of
reduced GSH into hydrophobic and elec-
trophilic compounds (Strange et al. 2000),
along with other phase II enzymes (Hayes
and Pulford 1995).GSH and related enzymes
are also involved in cellular protection against
reactive oxygen species (ROS) (Hayes and
Pulford 1995; Ochi et al. 1994), and it has
been hypothesized that maintenance of the
cellular redox state may have an important
role in arsenic-related pathology (Anderson
1998; Schuliga et al. 2002).
Our goals in this study were to determine
whether there are associations between pri-
mary and secondary methylation ratios and
risk of skin lesions and whether these associa-
tions were modified by polymorphisms in
GSTM1, GSTT1, and GSTP1.
Materials and Methods
Study population. This case–control study
was conducted in the Pabna district of
Bangladesh and has been described previously
(McCarty et al. 2006). Briefly, two physi-
cians, trained by a dermatologist in character-
izing arsenic-related skin lesions, identified
eligible cases from the Pabna district.
Physicians were blind to the exposure status
of the subjects. Cases were at least 16 years of
age, with one or more type of skin lesion:
diffuse/spotted melanosis, diffuse/spotted
keratosis, hyperkeratosis, or leukomelanosis.
Cases often had more than one type of skin
lesion, so the various types of skin lesions
were grouped as one outcome. Controls were
clinically evaluated to be free of skin lesions
by visual inspection. Controls were selected
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OBJECTIVE: We investigated whether primary and secondary arsenic methylation ratios were
associated with skin lesions and whether GSTT1, GSTP1, and GSTM1 polymorphisms modify
these relationships. 
METHODS: A case–control study of 600 cases and 600 controls that were frequency matched on
age and sex was conducted in Pabna, Bangladesh, in 2001–2002. Individual well water, urine,
and blood samples were collected. Water arsenic concentration was determined using inductively
coupled plasma mass spectrometry (ICP-MS). Urinary arsenic speciation was determined using
high performance liquid chromatography hydride with generator atomic absorption spectrometry
and ICP-MS. Genotyping was conducted using multiplex polymerase chain reaction and
TaqMan. 
RESULTS: A 10-fold increase in primary methylation ratio [monomethylarsonic acid (MMA)/(arsenite
+ arsenate] was associated with a 1.50-fold increased risk of skin lesions (multivariate odds ratio =
1.50; 95% conﬁdence interval, 1.00–2.26). We observed signiﬁcant interaction on the multiplicative
scale between GSTT1 wildtype and secondary methylation ratio [dimethylarsinic acid/MMA; like-
lihood ratio test (LRT), p = 0.01]. No signiﬁcant interactions were observed for GSTM1 or GSTP1
or for primary methylation ratios. 
CONCLUSION: Our ﬁndings suggest that increasing primary methylation ratios are associated with
an increase in risk of arsenic-related skin lesions. The interaction between GSTT1 wildtype and
secondary methylation ratio modiﬁes risk of skin lesions among arsenic-exposed individuals.
KEY WORDS: arsenic methylation, DMA, GST polymorphisms, methylation ratio, MMA, primary
methylation, secondary methylation. Environ Health Perspect 115:341–345 (2007).
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least 16 years, living in the same village as
cases but not sharing a tube well with cases.
Cases and controls were frequency matched
on sex and age (± 3 years). The participation
rate was 98.0%; 24 subjects from 1,224
declined to participate in the study. Of the
600 cases and 600 controls enrolled in the
study during 2001–2002, 11 people were
excluded from the analysis on the basis of age
or well-use duration. The population is ethni-
cally homogeneous. All study participants
gave informed consent. The protocol was
approved by the institutional review boards at
Dhaka Community Hospital, Bangladesh,
and Harvard School of Public Health.
We designed the study to investigate mod-
iﬁers of the association between arsenic expo-
sure and skin lesions, not the main effects.
Previous studies have investigated the main
effects of arsenic exposure through drinking
water and risk of skin lesions; however, studies
of effect modiﬁcation are not as common, par-
ticularly among regions of low exposure
(Ahsan et al. 2000; Fewtrell et al. 2005; Guha
Mazumder et al. 1998; Hsueh et al. 1997;
Rahman et al. 2006). Accordingly, approxi-
mately 80% of controls were selected from
suspected “low-exposure” arsenic (< 50 µg/L)
communities and 20% of the controls were
from suspected “high exposure” (≥ 50 µg/L)
areas. This distribution was chosen to repre-
sent the reported background distribution of
wells in Pabna (British Geological Survey and
Bangladesh Department of Public Health
and Engineering 2001) and to ensure hetero-
geneity of exposure. Individuals determined
to have arsenic exposure ≥ 50 µg/L, the
Bangladesh standard, were advised to change
their water source.
Interviews and sample collection.
Interview and sample collection has been
described previously (McCarty et al. 2006).
Briefly, trained interviewers collected infor-
mation through questionnaires regarding
exposure history, diet, and lifestyle factors as
well as collection of toenail, urine, and indi-
vidual well water samples. Data were collected
on liters of water/liquid per day, diet, disease
history, identification of current primary
water source (tube well), years of use, and use
of a previous tube well. 
Water samples were analyzed by the U.S.
Environmental Protection Agency (EPA)
Method 200.8 (U.S. EPA 1994) with induc-
tively coupled plasma mass spectroscopy
(ICP-MS) (Environmental Laboratory Services
North Syracuse, NY, USA). The method
limit of detection is 1 µg As/L. 
One 10-mL EDTA tube was used to col-
lect blood samples. Blood samples were stored
on ice in a cooler until they were returned to
the laboratory and processed with cell lysis
solution. Samples were shipped suspended in
cell lysis solution for DNA extraction and
genotyping at the Molecular Epidemiology
Laboratory, Harvard School of Public Health. 
Samples of all 10 toenails from each sub-
ject were placed in individual sealed envelopes
and were analyzed at Harvard School of
Public Health using ICP-MS according to a
previously published protocol (Chen et al.
1999).Rigorous quality assurance and control
procedures were employed, with 10% of each
batch of samples being repeated. Standard ref-
erence material water (NIST 1643d, Trace
Elements in Water; National Institute of
Standards and Technology, Gaithersburg,
MD, USA) and certiﬁedhuman hair reference
material (CRM Hair; Shanghai Institute of
Nuclear Research, Academia Sinica, China)
were used to validate instrument performance
and digestion methods. The net concentra-
tion was calculated by subtracting detectable
laboratory blank concentrations within each
batch. The reported arsenic concentrations
were corrected for systemic error by normaliz-
ing the sample concentrations against the
measured average dailyNIST 1643d Asin con-
centration. This corrected value was used in
all statistical analyses.
Spot urine samples (approximately
120 mL) were collected from each subject.
Urine samples were then aliquoted into two
15-mL tubes. Within 6 hr the samples were
stored in a –20°C freezer. The urine samples
were analyzed at a laboratory in Taiwan at the
Taipei Medical University for dimethyl-
arsonic acid (DMA), monomethylarsonic acid
(MMA), AsIII, and arsenate (AsV). High per-
formance liquid chromatography (HPLC)
was used to separate the urine samples. A
hydride generator atomic absorption spec-
trometer (HGAAS) was used to quantify the
levels of species of inorganic arsenic, AsIII, and
AsV and the metabolites of inorganic arsenic,
MMA and DMA. Urine samples were thawed
at room temperature, then dispersed by ultra-
sonication, and filtered through a Sep-Pack
C18 column (Mallinckrodt, Baker Inc.,
Phillipsburg, NJ, USA). A HPLC system
(Waters 501; Waters Assoc., Milford, MA,
USA) using a Nucleosil 10SB, 100A column
(Phenomenex, Torrence, CA, USA) was used
to separate arsenic species in each 200-µL
urine sample. The HPLC was linked to a
HGAAS for quantification of levels of AsIII,
AsV, MMA, and DMA. Inductively coupled
plasma mass spectrometry (ICP-MS) was also
used to determine the total concentration of
inorganic and organic arsenic in the urine
(Hsueh et al. 1997, 2002).
Genotyping. DNA samples were stored at
–80°C until processed. We evaluated the
GSTM1 and GSTT1 genetic polymorphisms
using a multiplex PCR technique, previously
described by our laboratory (Liu et al. 2001).
GSTP1 polymorphism was genotyped by the
5´ nuclease assay (TaqMan) using the ABI
Prism 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA).
The primers, probes, and reaction conditions
are available upon request. Genotyping for
GSTT1 and GSTM1 was completed for 1,062
subjects, and genotyping for GSTP1 was com-
pleted for 1,101 subjects. Genotyping was per-
formed by laboratory personnel blinded to
case–control status, and a random 5% of the
samples were repeated to validate genotyping
procedures. Two authors independently
reviewed all genotyping results with 100%
concordance.
Statistical analysis. Data were analyzed
using SAS software (version 8.2; SAS Institute
Inc., Cary, NC, USA). We calculated the pop-
ulation characteristics and tested the signifi-
cant differences between cases and controls
using the chi-square and t-tests where appro-
priate. The frequency distribution of the poly-
morphisms was tested among controls to
ensure Hardy-Weinberg equilibrium. The co-
dominant model was used for GSTP1.
Analysis was restricted to subjects who
reported well use for a period > 6 months to
minimize potential for variability in well
arsenic level. Subjects were frequency matched
by age and sex. These covariates were included
in all regression models. Arsenic level and vol-
ume of liquid consumed per day were not
combined as a dose variable, as liquid volume
included juice, milk, soup, and tea in addition
to water. Smoking status, betel nut use, and
chewing tobacco use were dichotomous cate-
gorical variables. Primary methylation ratio
was defined as the concentration of MMA/
inorganic arsenic. Secondary methylation was
deﬁned as the concentration of DMA/the con-
centration of MMA (Chen et al. 2003a,
2003b). Generalized additive models (GAMs)
were used to allow ﬂexibility in modeling the
data by relaxing the linearity assumption
(Hastie and Tibshirani, 1990). Data explo-
ration using GAMs suggested that the log-
odds of case identiﬁcation varied linearly with
the log of primary methylation and secondary
methylation ratios. Consequently, log-trans-
formed primary methylation ratio and sec-
ondary methylation ratio were treated as
continuous variables in regression models. The
log-odds of case status varied linearly with the
arsenic levels of well water; consequently,
untransformed arsenic concentration was
treated as a continuous variable in regression
models. The log-odds of case status had a qua-
dratic relationship with body mass index
(BMI). To express potential quadratic effects,
two BMI terms were used: BMI centered by
subtracting its median, 19.1, and the square of
the centered BMI. Consolidated categories for
educational status and age, were established.
GAM analysis was conducted in R (version
1.8.1; http://www.r-project.org/).
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relative risk, and corresponding 95% confi-
dence intervals (CIs) were computed for skin
lesions in relation to primary and secondary
methylation ratio indices by using uncondi-
tional logistic regression analyses. All regres-
sion models included age and sex as covariates.
To control for potential confounding effects,
we adjusted all calculations of ORs for skin
lesions for level of education, smoking status,
use of betel nut, use of chewing tobacco,
BMI, and previous well use. Models were
adjusted for the main effects of GSTT1,
GSTM1, or GSTP1. Likelihood ratios tests
were used to determine multiplicative inter-
action. Separate logistic regression analyses
were performed in various genotype strata to
assess evidence of effect modification.
Additionally, effect modiﬁcation was consid-
ered using, likelihood ratio tests (LRT), com-
paring adjusted models with main effects for
GST polymorphisms and methylation ratios
and an interaction term compared with a
model with the main effects only.
Results
Demographic data are presented in Table 1.
Of 592 cases, diffuse melanosis accounted for
31.7% of the cases (n = 377), followed by
leukomelanosis (n = 342), spotted melanosis
(n = 145), diffuse keratosis (n = 117), spotted
keratosis (n = 73), and hyperkeratosis (n = 40).
Subjects often had multiple types of lesions;
thus specific types were not analyzed sepa-
rately. Cases and controls were not signifi-
cantly different in terms of age, education,
BMI, or sex. Controls reported longer dura-
tion of current well use, and cases reported a
higher frequency of previous well use. Cases
had significantly higher well and toenail
arsenic concentrations than controls. Cases
and controls reported similar ﬂuid consump-
tion. Cases reported more frequent betel nut
use; however, no significant differences were
observed in years of betel nut use and number
of betel nuts chewed per day. Cases reported
chewing tobacco use more frequently than
controls; however, there was no difference in
years of chewing tobacco use. Controls
reported current or former cigarette use more
frequently than cases. 
Cases had significantly higher total uri-
nary arsenic, DMA, MMA, AsIII, and total
inorganic arsenic concentrations than controls
(Table 2). Based on the bivariate analysis,
cases and controls had significantly different
primary and secondary methylation ratios.
The frequency of the GST polymorphisms
was similar between cases and controls. 
In a multivariate model, a 10-fold increase
in primary methylation ratio was associated
with a 1.50-fold increase in odds of skin lesions
(95% CI, 1.001–2.26). We did not observe a
significant association between secondary
methylation ratio and risk of skin lesions
(OR = 0.90; 95% CI, 0.81–1.03). The associa-
tion between primary methylation ratio and
skin lesions remained similar after adjustment
for the GSTT1, GSTM1, or GSTP1 genotypes. 
Adjusted ORs for the main effects of the
methylation ratios on the outcome of skin
lesions, stratiﬁed by genotype are presented in
Table 3. For individuals with the GSTT1
wildtype genotype, a 10-fold increase in pri-
mary methylation ratio was associated with a
1.67 increased risk of skin lesions (95% CI,
1.06–2.64). We did not detect a significant
effect modiﬁcation between GSTT1, GSTM1,
or GSTP1 genotypes and primary methylation
ratio and risk of lesions. 
In GSTT1 wildtype individuals, a 10-fold
increase in secondary methylation ratio was
associated with 0.87 odds of skin lesions com-
pared to GSTT1 null (OR = 0.87, 95% CI,
0.76–0.99). We did not detect a significant
association between secondary methylation
ratio and skin lesions for the GSTT1 null geno-
type. We evaluated a genotype-methylation
Urinary arsenic methylation, GSTs, and skin lesions
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Table 1. Characteristics of skin-lesion cases and population-based controls in Pabna, Bangladesh.







Mean age (years)  33.7 ± 12.6 (597) 33.9 ± 12.7 (592) 0.78
Body mass index (kg/m2)  20.4 ± 3.1 (597) 20.1 ± 3.1 (592) 0.17
Percent male 60.30 (360) 60.30 (357) 0.94
Mean duration of present well use (years) 10.1 ± 9.0 (592) 8.0 ± 7.2 (592) < 0.0001
Percent reported a previous well 2.84 (17) 7.77 (45) 0.0002
Percent ever used betel nuts 24.30 (145) 27.70 (164) 0.19
Mean years of betel nut use  10.8 ± 8.9 (143) 11.0 ± 9.5 (160) 0.84
Mean number of betel nuts chewed per day  5.6 ± 3.6 (158) 5.7 ± 3.8 (149) 0.69
Percent chew tobacco leaves  16.40 (587) 17.10 (590) 0.05
Mean years of tobacco leaves chewed  9.9 ± 9.1 (95) 10.9 ± 9.4 (95) 0.46
Percent smoke cigarettes currently 30.50 (597) 26.70 (592) 0.14
Percent ever smoked 31.00 (597) 28.70 (592) 0.37
Education level (597) (592) 0.0005
Percent illiterate 17.40 (104) 22.90 (136)
Percent literate (incomplete primary education) 23.80 (142) 29.40 (174)
Percent completed primary education 11.70 (79) 11.80 (70)
Percent completed middle school education 31.90 (191) 23.50 (139)
Percent completed secondary education or more 13.60 (81) 26.00 (154)
aValues are mean ± SD except where noted; n values are in parentheses.
Table 2. Measures of arsenic exposure, biomarkers of exposure and methylation capacity, and GST
genotypes.
Controlsa Casesa p-Value
Mean arsenic level of current well (µg/L) 38.0 ± 99.0 (595) 174.0 ± 265.0 (592) < 0.0001
Mean arsenic level in nail sample (µg/g)  2.8 ± 4.1 (583) 5.9 ± 7.4 (589) < 0.0001
Mean daily total water/liquid consumption (L)  3.8 ± 1.2 (595) 3.7 ± 1.1 (592) 0.07
Mean total urinary arsenic concentration (µg/L) 51.79 ± 171.8 (597) 147.69 ± 230.8 (592) < 0.001
Mean inorganic arsenic concentration (µg/L) 14.2 ± 28.2 (597) 21.4 ± 39.5 (592) 0.0003
Mean percent inorganic arsenic  12.80 (597) 12.90 (592) 0.50
Mean DMA concentration (µg/L)  70.0 ± 121.3 (597) 101.0 ± 152.3 (592) 0.0001
Mean percent DMA  73.80 (597) 72.40 (592) 0.05
Mean MMA concentration (µg/L)  14.9 ± 28.5 (597) 25.4 ± 49.7 (592) < 0.0001
Mean percent MMA 14.90 (597) 13.80 (592) 0.01
Mean AsV concentration (µg/L)  4.1 ± 12.6 (597) 4.3 11.3 (592) 0.69
Mean AsIII concentration (µg/L)  10.1 ± 23.8 (597) 17.1 ± 35.2 (592) < 0.0001
Mean primary methylation ratio  1.3 ± 1.1 (597) 1.4 ± 1.2 (592) 0.23
Mean secondary methylation ratio  7.9 ± 7.5 (597) 7.5 ± 8.5 (592) 0.32
GSTT1 0.37
Null (17.9%) 18.80 (112) 16.90 (100)
Wildtype (82.12%) 81.20 (483) 83.10 (491)
GSTM1 0.99
Null (41.1%) 41.00 (244) 41.80 (243)
Wildtype (58.9%) 59.00 (351) 58.20 (348)
GSTP1 0.57
AA (53.8%) 53.60 (314) 54.00 (317)
AG (38.7 %) 40.30 (236) 37.10 (218)
GG (7.5%) 6.10 (36) 8.90 (52)
aValues are mean ± SD except where noted; n values are in parentheses.ratio interaction model using methylation ratio
as a continuous variable and the GSTT1 geno-
type and found evidence of effect modiﬁcation
by the GSTT1 wildtype genotype on risk of
skin lesions ( LRT p-value = 0.01). 
We did not detect a signiﬁcant association
between primary or secondary methylation
ratios and skin lesions for the GSTM1 geno-
type or effect modification by GSTM1 on a
multiplicative scale for the association
between skin lesions and primary or sec-
ondary ratios. Additionally, we did not detect
a significant association between primary or
secondary methylation indices and skin
lesions by the GSTP1 genotypes.
Discussion
As defined, increasing primary [MMA/
(AsIII+AsV)] or secondary (DMA/MMA)
methylation ratios would indicate more effec-
tive methylation of arsenic metabolites (Chen
et al. 2003a, 2003b; Del Razo et al. 1997;
Loffredo et al. 2003).We observed an overall
increase in ORs of skin lesions associated with
increasing primary methylation ratio. Since the
function of primary methylation is to metabo-
lize AsIII to MMAIII, these results are consistent
with the hypothesis that increased production
of MMAIII is a mechanism that may contribute
to the adverse health effects associated with
chronic arsenic exposure. Previous studies of
populations in Taiwan have reported that skin
cancer, including skin lesions in one study,
were associated with increased primary methy-
lation (Hsueh et al. 1997; Yu et al. 2000). A
study of bladder cancer and arsenic exposure
through drinking water described similar ﬁnd-
ings, although it is noted the mechanism for
arsenic exposure and skin lesions is likely to be
different than for bladder cancer (Chen et al.
2003b). Two studies in Taiwan found that skin
cancer, including basal cell carcinoma, squa-
mous cell carcinoma, and premalignant skin
lesions, was associated with a higher percentage
of MMA in the urine of exposed individuals
than in controls, and these ﬁndings were consis-
tent with ﬁndings from a study in a population
in Mexico (Chen et al. 2003a; Del Razo et al.
1997; Hsueh et al. 1997). Additionally, a recent
study has reported that MMAIII concentration
in the urine of arsenic-exposed individuals was
significantly higher in individuals with skin
lesions (Valenzuela et al. 2005).
An increase in secondary methylation of
arsenic was associated with a decreased risk of
skin lesions in our study; however, this ﬁnd-
ing was not statistically significant. Controls
were found to have signiﬁcantly higher mean
secondary methylation ratios than cases in our
study population. Previous studies have
reported that a decrease in secondary methy-
lation ratio was associated with an increased
risk of skin cancer with elevated arsenic expo-
sure (Hsueh et al. 1997; Yu et al. 2000), and
lower secondary methylation ratios were asso-
ciated with an increased risk for bladder can-
cer in an arsenic-exposed population (Chen
et al. 2003b).
Phase II metabolic GST enzymes conju-
gate metabolic intermediates into more solu-
ble forms, which are then excreted by the
body. It may be hypothesized that when the
individual lacks the enzyme activity and is
exposed to a xenobiotic compound, the indi-
vidual would be at a greater risk of disease
(Hayes and Pulford 1995; Strange et al.
2000). However, in arsenic metabolism where
the products of primary and secondary methy-
lation (MMAIII and DMAIII) are suspected to
be more reactive than their metabolic precur-
sors MMAV and DMAV, individuals with
high detoxifying ability may be at greater risk
of adverse effects associated with chronic
arsenic exposure through drinking water
(Del Razo et al. 2001; Kitchin 2001).
The mechanism for arsenic-induced skin
lesions is not known nor is arsenic metabo-
lism in humans fully understood. It is
accepted that the level of cellular GSH is cen-
tral to methylation (Anderson 1998; Kitchin
2001; Sakurai et al. 2004). It has been
reported that the production of MMAV
increases the activity of GST enzymes
(Sakurai et al. 2002). Results of in vivo experi-
ments identiﬁed that a GST enzyme, GST Ω,
has been found to reduce MMAV to MMAIII
and to catalyze the conjugation of cellular
glutathione and MMAIII. It is proposed this
depletion of GSH may be responsible for
increased accumulation levels of MMAV and
increased toxicity (Zakharyan et al. 2001).
Although the role of GST τ is not known in
arsenic metabolism, it is possible that GSTT1
may have a similar function or that this
polymorphism is in linkage disequilibrium
with another polymorphism responsible for
this observed effect. It was also noted by
another study that the cytotoxicity of MMAV
is between inorganic arsenic and DMAV in
v79 cells (Eguchi et al. 1997); however, in the
depletion of GSH by an inhibitor of GSH
synthase or GSH reductase, MMAV is weakly
cytotoxic (Biggs et al. 1997). Further mecha-
nistic work is needed to determine the role of
GST τ in arsenic metabolism.
Although the observation that the GSTT1
null genotype modifies the association
between secondary methylation and skin
lesions is somewhat unexpected, some evi-
dence exists for its biological plausibility.
DMA is the metabolite produced at the end of
secondary methylation. It has been reported
that DMA conjugates with GSH, and this
conjugate is responsible for apoptosis after
GSH depletion (Sakurai et al. 2002). A previ-
ous study of GST polymorphisms and arsenic
urinary metabolites reported that subjects with
the GSTT1 null genotype had an increased
percentage of DMA in their urine (Chiou et al.
1997), however, we did not ﬁnd a signiﬁcant
difference in percentage of DMA in GSTT1
null compared with wildtype. The activity of
GST τ in those that are GSTT1 wildtype may
deplete levels of GSH earlier than those that
are GSTT1 null, so it is plausible that different
stages of methylation (primary vs. secondary)
are important in terms of accumulation of
compounds that may be related to some of the
adverse effects of chronic arsenic exposure. In
a previous analysis, we reported that the
GSTT1 homozygous wildtype genotype (OR
= 1.56; 95% CI, 1.10–2.19) and the GSTP1
GG polymorphism were associated with
greater odds of skin lesions, (OR = 1.86; 95%
CI, 1.15–3.00) compared with the null and
GSTP1 AA genotypes, respectively. (McCarty
KM, unpublished data)
Although several studies have reported the
methylation ability and compared differences
in metabolite concentrations between cases
and controls, sex, or age groups, this is the ﬁrst
study to predict odds of skin lesions based
upon methylation ratios (Chiou et al. 1997;
Del Razo et al. 1997, 2001; Vahter et al.
1995).Previous studies have explored the rela-
tionship with skin cancer, including skin
lesions; however, skin lesions are considered
noncancerous outcomes and may have a dif-
ferent biologic mechanism (Chen et al. 2003a;
Hsueh et al. 1997; NRC 1999; Yu et al.
2000). Methylation ability is stable within an
individual and not inﬂuenced by arsenic expo-
sure (Chiou et al. 1997; Hopenhayan-Rich
et al. 1996). The results of the HPLC-
HGAAS ICP-MS method are not inﬂuenced
by the presence of arsenobetaine or arseno-
choline in urine, which arises from the organic
arsenic contributed through diet (Hsueh et al.
1997). The use of the unadjusted urinary
arsenic concentration from the ﬁrst morning
McCarty et al.
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Table 3. Adjusted odds of skin lesions associated with methylation index stratiﬁed by genotype.
Primary methylation ratio Secondary methylation ratio
Strata OR (95% CI) OR (95% CI)
GSTT1 null 0.72 (0.26–2.02) 1.21 (0.89–1.63)
GSTT1 wildtype 1.67 (1.06–2.64) 0.87 (0.76–0.99)
GSTM1 null 1.93 (0.92–4.04) 0.89 (0.73–1.09)
GSTM1 wildtype 1.27 (0.78–2.09) 0.95 (0.81–1.11)
GSTP1
AA 1.22 (0.69–2.14) 0.83 (0.70–0.99)
AG 2.02 (0.99–4.10) 0.97 (0.78–1.19)
GG 2.23 (0.47–10.62) 1.10 (0.66–1.84)voids is an important factor in helping to
minimize the effect of fluctuations in urine
concentration that were unrelated to exposure
(Biggs et al. 1997). Creatinine adjustment
corrects for the consumption of nonarsenic-
containing fluids, which dilutes urinary
arsenic, and for exercise, which increases con-
centration (Biggs et al. 1997). However, the
food frequency questionnaire administered in
this study indicated that beverages other than
tea and water were not frequently consumed.
Additionally, it was found in several studies
that creatinine adjustment may not be neces-
sary in population studies of environmental
inorganic arsenic exposure (Hinwood et al.
2002). We did not adjust for urinary creati-
nine in this analysis.
We acknowledge that we were unable to
distinguish and quantify the trivalent methy-
lated metabolites in the urine (MMAIII and
DMAIII). The trivalent species are very sensi-
tive and measurement must occur soon after
collection, making it impractical for this
study design (Valenzuela et al. 2005). 
Several factors related to general health
may affect methylation ability. Liver cirrhosis
results in signiﬁcantly less MMA and signiﬁ-
cantly more DMA in urine excretion (Geubel
et al. 1998). Arsenic exposure may increase
risk of diabetes or hypertension (Rahman et al.
1998, 1999). Hypertension and diabetes affect
the renal system, which may alter urinary
arsenic ratios. Infection and diet can inﬂuence
urinary pH and possibly affect urinary ratios.
Based on self-report of health status, we do
not believe this would have significantly
affected our results; however we acknowledge
this potential limitation.
There may be some degree of bias intro-
duced by the grouping of several types of skin
lesions into one outcome category. We
acknowledge that different biological mecha-
nisms may be responsible for the various types
of skin lesions. Many subjects had more than
one type of skin lesion. Any bias introduced
by this categorization would bias the results
toward the null.
The metabolism of arsenic in human and
the mechanism for arsenic-related skin lesions
is unclear. The relationship between methyla-
tion capacity and skin lesions needs further
investigation. The ﬁndings of this study sug-
gest new genotype–phenotype links and addi-
tional mechanistic studies are necessary to
elucidate the precise mechanisms of these
interactions between GSTT1 and arsenic
methylation capacity. 
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